Figure 3. In vitro antitumor efficacy and identification of targeted pathways and enzymes by novel pyrrolo[3,2-d]pyrimidine analogs in H460 tumor cells by proliferation assays.

Dose-response growth inhibition curves are shown for AGF94, an established GARFTase inhibitor (43), and for AGF291, AGF320, and AGF347 without additions, or in the presence of adenosine (60 μM) and/or glycine (130 μM). The results are mean values +/−standard deviations for three biological replicates.